As the demand for COVID vaccines decreases worldwide, Moderna is planning to release a RSV vaccine, pending U.S. approval.
This upward trend is apparent, with the current average reflecting a 19.56% increase from the previous average price target ... validated with its COVID-19 vaccine, which was authorized in the United ...